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Abstract Bone sarcoma as a second malignancy is rare
but highly fatal. The present knowledge about radiation-
absorbed organ dose–response is insufficient to predict the
risks induced by radiation therapy techniques. The objec-
tive of the present study was to assess the treatment-
induced risk for bone sarcoma following a childhood
cancer and particularly the related risk of radiotherapy.
Therefore, a retrospective cohort of 4,171 survivors of a
solid childhood cancer treated between 1942 and 1986 in
France and Britain has been followed prospectively. We
collected detailed information on treatments received dur-
ing childhood cancer. Additionally, an innovative meth-
odology has been developed to evaluate the dose–response
relationship between bone sarcoma and radiation dose
throughout this cohort. The median follow-up was
26 years, and 39 patients had developed bone sarcoma. It
was found that the overall incidence was 45-fold higher
[standardized incidence ratio 44.8, 95 % confidence inter-
val (CI) 31.0–59.8] than expected from the general popu-
lation, and the absolute excess risk was 35.1 per 100,000
person-years (95 % CI 24.0–47.1). The risk of bone sar-
coma increased slowly up to a cumulative radiation organ
absorbed dose of 15 Gy [hazard ratio (HR) = 8.2, 95 % CI
1.6–42.9] and then strongly increased for higher radiation
doses (HR for 30 Gy or more 117.9, 95 % CI 36.5–380.6),
compared with patients not treated with radiotherapy. A
linear model with an excess relative risk per Gy of 1.77
(95 % CI 0.6213–5.935) provided a close fit to the data.
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These findings have important therapeutic implications:
Lowering the radiation dose to the bones should reduce the
incidence of secondary bone sarcomas. Other therapeutic
solutions should be preferred to radiotherapy in bone sar-
coma-sensitive areas.
Keywords Bone sarcoma  Childhood cancer 
Iatrogenous effects  Radiation therapy  Secondary tumor
Introduction
Excess of incidence and mortality from a second malignant
neoplasm (SMN) is an increasing concern among survivors
of childhood cancers (Reulen et al. 2011; Olsen et al. 2009;
Friedman et al. 2010; Bassal et al. 2006). Despite their
rarity, sarcomas accounted for 19 % of the SMN among
survivors aged less than 15 years, 10 % among those aged
15–39 years, 5 % among those aged 40–59 years and
almost 0 % for older ages (Olsen et al. 2009). Moreover,
bone sarcoma exhibits the highest overall standardized
incidence ratio (SIR) for any SMN category (Reulen et al.
2011). However, although radiation dose has been dem-
onstrated to be a major risk factor, the role of radiation
dose in the risk of secondary bone sarcoma among survi-
vors of childhood cancers is currently unclear. Indeed,
case–control studies investigating the relation between the
radiation dose at a particular bone site and the risk of
developing bone sarcoma at this site have reached widely
different conclusions (Berrington de Gonzalez et al. 2012;
Henderson et al. 2012; Kleinerman et al. 2005; Le Vu et al.
1998; Hawkins et al. 1996; Wong et al. 1997; Tucker et al.
1987). This may be due to insufficient follow-up or because
of the design of the case–control studies in which evalua-
tion of the dose–response relationship requires the use of
the ‘‘local dose’’ of radiation at the sarcoma site of the case
and at the same site for its matched controls. When nested
in a cohort, practical constraints related to control selection
may induce reduction in the case–control study sample and
therefore cause some biases.
The highlights of the current study, in addition to being
based on a valuable dataset with a long follow-up, are that
detailed information on radiotherapy was available and
estimates of radiation dose at many sites in each bone were
performed for each subject; thus, one could explore the
dose–response relationship in a cohort study design instead
of through the usual case–control analysis design, taking
full advantage of the available data.
The purposes of this cohort study were (1) to investigate
the role of the radiation dose in the risk of secondary bone
sarcoma in survivors of childhood cancer; (2) to identify
primary neoplasm types that contribute most to the risk of
secondary bone sarcoma; and (3) to develop an innovative
approach that allows modeling of the dose–response rela-




A cohort of 4,171 children treated in France and Britain
was constituted between 1985 and 1995, comprising
patients who were alive without secondary bone sarcoma
5 years after a first solid cancer diagnosis made before the
year 1986 and before the ages of 16 years for French
patients and 15 years for English patients, who were fol-
lowed up thereafter. One hundred and forty-three patients
who had an osteosarcoma as the first cancer were excluded
because, in the case that they developed bone sarcoma
during follow-up, it would be impossible to determine
whether the bone sarcoma was a second cancer or a
recurrence of the first lesion. However, patients treated for
Ewing’s sarcoma in their childhood were not excluded
because if they developed bone sarcoma as second cancer,
one would be able to determine whether it was a recurrence
or a new cancer, based on histology.
Follow-up for the occurrence of death or second cancer
of the 2,967 French patients from the diagnosis of child-
hood cancer relied exclusively on medical records from the
treatment centers and general practitioners and a self-
completed questionnaire. Cancers declared from the ques-
tionnaire were required to be validated by contacting the
general practitioner or checking medical records; other-
wise, they were not taken into account in analyses. This
questionnaire was based on that used in the British
Childhood Cancer Survivor Study (Hawkins et al. 2008). A
total of 1,825 patients returned the completed questionnaire
(sent to 2,449 alive patients) by December 31, 2010, which
is the end point of our study.
A total of 1,204 British patients were followed up for the
occurrence of a second cancer and death using the National
Health Service Central Registers (Office of National Sta-
tistics 2006; Hawkins and Swerdlow 1992). They were
followed up until the occurrence of a bone sarcoma, their
death or December 31, 2006, whichever came first.
Case–control sampling
To make our results more comparable to those of published
case–control studies, a nested case–control analysis was
also performed within the cohort. Five controls were
individually matched to second cancer sarcoma cases on
sex, age, year of diagnosis, type of first cancer and duration
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of follow-up since the first cancer diagnosis. In this ana-
lysis, a case could potentially serve as a control for a case
that had occurred earlier.
Case identification
A case was characterized by a patient having a tumor
whose histology was defined as a bone sarcoma in the ICD
(ICD codes 170.0–170.9). French bone sarcoma cases were
identified from self-questionnaire, medical records and the
National Registry of Causes of Death. English bone sar-
coma cases were identified from the National Health Ser-
vice Central Registers (Hawkins and Swerdlow 1992).
Only bone sarcoma cases validated through a copy of the
pathological record were considered as cases.
Radiation dosimetry
Retrospective dosimetric estimation was performed by
reconstructing the body, i.e., developing a mathematical
phantom of the individual patient from medical data files,
at the time of treatment (Francois et al. 1988a, b) and the
radiation therapy circumstances for each patient. Radiation
doses were estimated at 188 points, fairly spatially allo-
cated in the human body, from which 80 were located in
bones. The Dos_EG software used was developed specifi-
cally for these dose calculations (Shamsaldin et al. 1998;
Diallo et al. 1996; Francois et al. 1988a, b).
In the cohort analysis, the radiation dose was estimated
in 59 bones for each of the 2,879 patients who had received
radiotherapy during the follow-up period, i.e., up to 2 years
before the end of their follow-up, because it is believed that
the iatrogenic effects of radiotherapy do not appear within
2 years of treatment. If several points for which doses have
been estimated were located within the same bone (some
long bones, such as the femur, are long enough that two
estimation points have been allocated within them), the
mean dose was attributed to obtain a single dose by bone.
In this case, the bone dose was more representative of the
mean bone radiation dose than if the dose was estimated
just based on one point into the bone. Obviously, if we
could have estimated hundreds of doses in each bone, the
accuracy of the average bone dose would have been much
better, but unfortunately, we did not have these data.
However, we do not expect it would affect the risk esti-
mates significantly.
In the case–control study, only the local dose of radia-
tion was considered, which means that for each case, the
dose to the bone sarcoma site has been estimated, and for
each matched control, the dose to the same site has also
been estimated.
No dose estimation was performed for patients treated
with brachytherapy because the focus was only on external
radiotherapy here. Hence, five cases were excluded from
the dose–response relationship estimation for this reason.
Bones
To take into account the wide heterogeneity of the radia-
tion dose delivered throughout the body during radiation
therapy, the radiation dose received at the bone level was
considered here. The average human adult skeleton con-
sists of 206 bones (Ramé and Thérond 2006). Bones of the
arms, hands and feet (altogether 112 bones) were not
considered because of the lack of precision concerning the
position of the patient during the radiotherapy courses (two
cases excluded, Fig. 1). Apart from these bones, there was
missing information on several small bones of the face and
mini-bones (a total of 23 bones). However, all the 71
remaining bones, i.e., the largest in terms of volume, had
radiation dose estimated at least at one point and were thus
all taken into account. The body of each patient was
divided into 59 bones (ribs were grouped in pairs; Fig. 2).
Chemotherapy quantification
Drugs were grouped into seven classes according to their
known mechanisms of action in the cell: vinca alkaloids,
antimetabolites, alkylating agents, anthracyclines, cyto-
toxic antibiotics, epipodophyllotoxins and other drugs. The
total cumulative amount of drugs administered for each
class was expressed in moles per square meter, but also
calculated in milligrams per square meter, as usual. Doses
were expressed per square meter to take account of the
body surface area that was used for dose administration.
Statistical methods
The SIRs of bone sarcoma were estimated as the ratio of
observed to expected overall numbers of incident cases of
bone sarcoma. The expected number of incident cases of
bone sarcoma was defined as the number of person-years of
follow-up in the given cell multiplied by the corresponding
incidence rate of bone sarcoma from the British national
cancer incidence rates (Office of National Statistics 2006).
Fig. 1 Study population according to analyses; BS bone sarcoma
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British rates were used for patients both in France and in
Britain because no reference incidence rate estimates of
bone sarcoma were available in France. Inference for the
SIR relied on exact calculations based on the Poisson
distribution of the observed number of events (Belot et al.
2008). The absolute excess risk (AER) was estimated as the
difference between the observed and expected number of
incident bone sarcomas, divided by the number of person-
years of follow-up.
Each bone of the same child could have received very
different radiation doses during radiotherapy courses. We
therefore performed analyses of the relationship between
the radiation doses received and the risk of bone sarcoma
using the bone as the statistical unit. In this analysis, each
patient represented 59 bones, except for the 99 patients
who had had a leg amputated, for whom only their
remaining bones were taken into account. This method
requires that every bone of each patient from the cohort is
accounted for (if not amputated), in order to allow com-
parisons between the same bones of different patients.
As the dynamics of bone growth and radiation sensi-
tivity were likely to be more similar among bones of the
same structure and in the same area than between those in
various areas of the body, six skeleton parts were defined
within the human body in order to run a parsimonious
stratified analysis: the head, the pectoral girdle, the ribs, the
spine, the pelvis and the legs. Thanks to this type of ana-
lysis, bones were compared with other bones of the same
area of the skeleton and this allowed us to take into account
radiosensitivity heterogeneity in the whole body. In other
words, this method did not allow for reducing radiation
dose heterogeneity, but for better considering it and
reducing variance of risk estimates.
An internal analysis was conducted using Cox’s pro-
portional hazard regression model for clustered data, in
order to account for the lack of independence between the
bones of the same patient, and with stratification on skeleton
parts. The marginal approach of Wei et al. (1989), using
robust ‘‘sandwich’’ variance estimates, was used. The Fine
and Gray method with multiple imputations was used to
take into account death as a competing risk (Pintilie 2011;
Fine and Gray 1999; Ruan and Gray 2008; Resche-Rigon
et al. 2006; Gooley et al. 1999). Therefore, the cumulative
incidence and its variance were calculated based on the
Marubini and Valsecchi formula (Marubini and Valsecchi
1995, p. 341, equation 10.12). In these models, the time-
scale was attained age, and entry time was the age at
diagnosis of the first cancer plus 2 years for French and
5 years for English patients (Thiebaut and Benichou 2004).
In order to evaluate the dose–response relationship
between the bone radiation dose and the risk of bone sar-
coma, the following models were fitted within Cox
regression (Breslow and Day 1987):
1. Basic: hazard ratio = 1
2. Linear: hazard ratio = 1 ? b1dose
Fig. 2 Construction of the cohort of bones
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3. Linear quadratic: hazard ratio = 1 ? b1dose ?
b2dose
2
4. Linear exponential: hazard ratio = (1 ? b1dose) 9
ecdose
5. Linear quadratic exponential: hazard ratio = (1 ? b1
dose ? b1dose
2) 9 ecdose
with dose denoting the radiation dose to the bone.
Nested models were compared using the likelihood ratio
test, and confidence intervals (CIs) for model parameters
were estimated using profile likelihood (Moolgavkar and
Venzon 1987). Only results derived from the selected
model have been reported in this paper.
Due to the small number of incident bone sarcoma cases
in each skeleton part (16 cases at most), a separate analysis
for each set would have been underpowered. Consequently,
only overall analyses of the whole skeleton, with stratifi-
cation on the skeleton parts, were performed.
In the case–control analysis, conditional logistic
regression was used. The adjustment variables were the
same as in the cohort analysis, namely gender, age at
diagnosis of the first cancer, type of first cancer, chemo-
therapy administration, number of drugs and spinal dose of
radiation.
The EPICURE statistical software (Preston et al. 1993)
and SAS 9.3 (SAS Inst. Inc., Cary, NC) were used for the
analyses. All tests were two-sided, and a p value below
0.05 was considered significant. The proportional hazard
assumption was verified in the final model.
Results
Cohort
The median follow-up of 4,171 patients was 26 years fol-
lowing the diagnosis of the first cancer (Table 1). From 5 to
37 years of age, 39 patients had developed bone sarcoma in
16 different bones. The majority of bone sarcomas devel-
oped in the legs (12) or head (11). Most of these cases had
developed osteosarcoma (30); five had developed chon-
drosarcoma; and the four other cases had developed his-
tiocytofibroma (2), Ewing’s sarcoma and sarcoma without
further precision. Of these cases, 27 were men and 12
women (p = 0.08). Among the 2,879 patients who had
received radiotherapy during the follow-up period, 33 had
developed bone sarcoma. The median absorbed dose of
radiation to the bones was 0.48 Gy (range
0.00–179.83 Gy).
The cumulative incidences of bone sarcoma at 10, 20
and 35 years of age were, respectively, 0.3 % (95 % CI
Table 1 General characteristics





a For irradiated patients only,
except for those treated by
brachytherapy. Not available for
arms
Country France Britain
No. of patients (%) 2,967 (71.1) 1,204 (28.9)
Years of treatment:
median (range)
1977 (1946–1985) 1974 (1942–1985)
Age at diagnosis in years:
median (range)
4 (0–20) 5.0 (0–15)
Follow-up in years:
median (range)
26 (5–61) 28 (5–62)
Sex: no. (%) of males/no.
(%) of females
1,626 (54.8)/1,341 (45.2) 675 (56.1)/529 (43.9)
First cancer treatment no. (%)
Neither CT nor RT 212 (7.1) 196 (16.3)
CT but no RT 681 (23.0) 203 (16.9)
RT but no CT 578 (19.5) 363 (30.1)
RT and CT 1,496 (50.4) 442 (36.7)
Death before end of study
no. (%)
561 (18.9) 233 (19.4)
Bone sarcomas during
follow-up no. (%)
35 (1.2) 4 (0.3)
Radiation dosea (Gy): median (range)
Head 0.5 (0–110) 0.5 (0–126)
Pectoral girdle 0.7 (0–180) 0.6 (0–90)
Ribs 1.0 (0–99) 0.6 (0–90)
Spine 1.1 (0–111) 0.6 (0–99)
Pelvis 0.8 (0–47) 0.3 (0–61)
Legs 0.1 (0–81) 0.1 (0–96)
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0.1–0.4 %), 0.9 % (95 % CI 0.6–1.2 %) and 1.1 % (95 %
CI 0.8–1.5 %). The overall incidence was about 45-fold
higher than expected in the general population (95 % CI
31.0–59.8) (Table 2).
The SIR stabilized then decreased with increasing
attained age (Table 2), except that the SIR was higher after
30 years than between 20 and 29 years. No trend was
found concerning the SIR with time since first cancer
diagnosis. Also, no trend of the AER was observed with
time since first cancer diagnosis, nor with increasing
attained age. Both the SIR and AER were higher following
radiotherapy plus chemotherapy than they were following
either of these modalities alone.
In the univariate analysis, type of first cancer and risk of
bone sarcoma as a secondary cancer were closely linked
(Table 3, p \ 0.001). Patients who had retinoblastoma,
Ewing’s, soft tissue sarcomas and Hodgkin’s disease had a
significantly higher risk of bone sarcoma than patients who
had a nephroblastoma as the first cancer.
Bone sarcomas were more likely to occur in the pelvis
(HR = 49.2, 95 % CI 15.0–161.2), legs (HR = 11.0, 95 %
CI 3.9–31.1) and head (HR = 11.3, 95 % CI 3.9–32.4)
than in the trunk. After adjustment on the radiation dose,
hazard ratios were higher: 93.7 (95 % CI 27.2–327.6), 67.5
(95 % CI 18.3–249.1) and 12.9 (95 % CI 4.4–37.4) for
pelvis, legs and head, respectively.
Risk model for radiations
Upon modeling the association between the hazard rate of
bone sarcoma and bone doses, a linear model fitted the data
the most adequately (Fig. 3). The excess relative risk
(ERR) per Gy in this model was 1.78 (95 % CI 0.62–5.94).
This entailed the same hazard per additional Gray at low
(less than 1 Gy) as at high (more than 10 Gy) doses.
Compared with patients who did not receive radiation
therapy, the risk of bone sarcoma for those who received
more than 30 Gy was almost 120-fold higher (Table 4;
Fig. 3).
Chemotherapy
Chemotherapy administration was a nonsignificant risk
factor for bone sarcoma (HR = 1.9, 95 % CI 0.6–5.9) after










AER per 105 person-yearsb SIRc
Total 4,171 39 0.87 35.9 (24.8–47.9) 35.1 (24.0–47.1) 44.8 (31.0–59.8)
Years after diagnosis
5–9 4,171 14 0.27 42.8 (21.4–67.2) 41.9 (20.6–66.4) 51.9 (25.9–81.5)
10–19 3,867 21 0.37 56.8 (35.2–81.1) 55.8 (34.1–80.1) 56.8 (35.1–81.1)
20–29 3,388 3 0.15 11.7 (0.0–27.4) 11.1 (0.0–26.8) 20.0 (0.0–46.7)
C30 1,575 1 0.07 7.5 (0.0–22.4) 6.9 (-0.5 to 21.9) 14.3 (0.0–42.9)
Attained age (years)
5–9 4,171 4 0.06 28.7 (7.2–57.5) 28.3 (6.8–57.1) 66.7 (16.7–133.3)
10–19 4,088 27 0.45 85.2 (53.6–119.9) 83.8 (52.2–118.5) 60.0 (37.8–84.4)
20–29 3,643 4 0.22 12.2 (3.1–24.4) 11.5 (2.4–23.7) 18.2 (4.5–38.4)
C30 2,521 4 0.14 14.7 (3.7–29.3) 14.1 (3.2–28.8) 28.6 (7.1–57.1)
Age at diagnosis (years)
0–4 2,184 22 0.47 37.7 (22.3–54.9) 36.9 (21.5–54.1) 46.8 (27.7–68.1)
5–9 1,041 11 0.22 41.1 (18.7–67.2) 40.3 (17.9–66.4) 50.0 (22.7–81.8)
C10 946 6 0.18 25.4 (8.5–46.6) 24.7 (7.7–45.8) 33.3 (11.1–61.1)
Type of treatment
Surgery alone 408 1 0.09 8.0 (0.0–23.9) 7.3 (-0.7 to 23.3) 11.1 (0.0–33.3)
CT but no RT 884 5 0.17 25.2 (5.0–50.4) 24.4 (4.2–49.6) 29.4 (5.9–58.8)
RT but no CT 941 5 0.21 17.3 (3.5–34.7) 16.6 (2.7–33.9) 23.8 (4.8–47.6)
RT and CT 1,938 28 0.39 59.0 (37.9–82.2) 58.2 (37.1–81.3) 71.8 (46.2–100.0)
CT chemotherapy, RT radiotherapy, but no brachytherapy
a From the United Kingdom general population rates
b AER absolute excess risk, defined as [(observed - expected)/person-years]
c SIR standardized incidence ratio, defined as (observed/expected)
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adjustment. We failed to evidence a significant role for a
given drug category, even alkylating agents.
No interaction was found between the dose of ionizing
radiation and chemotherapy in the cohort (p = 0.20) or
case–control analysis (p = 0.43).
Evaluation of the approach
Odds ratios estimated from the nested case–control
study were higher than hazard ratio estimates from the
cohort analysis, with CI very much larger in the case–
control study due to the small number of cases
(Table 4). However, CI overlaps, hence there were no
statistical differences between the two approaches, but
that did not mean that they are similar. Nevertheless,
we strongly suppose that the nonsignificance is a
consequence of the lack of power due to the low
number of cases and that the cohort analysis was more
accurate.
Discussion
Despite the relatively large size of the cohort and the long
duration of follow-up, the main limitation of our study is
the small number of bone sarcomas: 39 cases, of whom
only 34 had available radiation doses.
Also, we were unable to take into account all the bones
of the body and the total radiation dose received by each
bone and its distribution. For example, for long bones such
as the femur, the radiation dose estimation was performed
only on two physical sites. Nonetheless, the radiation dose
was estimated in at least one site for the majority of bones.





Average bone dose (Gy),
mean, median (range)a
AER per 105 PYR
(95 % CI)
SIRb (95 % CI) Unadjusted HR
(95 % CI)
Nephroblastoma 2/851 72.7 6.6, 5.7 (0.1–24.5) 7.6 (20.8 to 20.3) 10.5 (0.0–26.3) 1 (Ref)
Neuroblastoma 2/573 55.2 5.1, 4.0 (0.1–29.1) 12.6 (20.8 to 32.7) 16.7 (0.0–41.7) 1.6 (0.2–11.5)
Hodgkin’s
disease
5/378 91.3 13.0, 12.6 (0.0–40.0) 51.2 (9.6–103.2) 62.5 (12.5–125.0) 6.2 (1.2–31.5)
Non-Hodgkin
lymphoma
3/459 59.5 5.8, 4.8 (0.1–25.0) 27.1 (20.8 to 64.3) 33.3 (0.0–77.8) 3.1 (0.5–18.4)
Soft tissue
sarcoma
11/535 62.6 3.2, 1.9 (0.0–17.4) 76.6 (34.4–125.8) 100.0 (45.5–163.6) 9.3 (2.0–41.8)
Ewing’s
sarcoma
6/141 92.2 3.8, 2.7 (0.0–16.8) 179.5 (59.2–329.7) 200.0 (66.7–366.7) 20.1 (4.1–98.8)
CNS tumor 1/690 83.0 8.0, 3.7 (0.3–35.0) 4.6 (20.7 to 15.3) 7.1 (0.0–21.4) 0.6 (0.1–6.9)
Gonadal tumor 1/227 38.3 7.9, 7.6 (0.5–28.8) 16.7 (20.7 to 51.5) 25.0 (0.0–75.0) 2.1 (0.2–22.7)
Retinoblastoma 7/144 81.3 1.8, 1.2 (0.1–26.3) 220.4 (62.3–410.0) 233.3 (66.7–433.3) 25.0 (5.2–120.9)
Other first
cancers
1/173 48.6 7.5, 6.4 (0.2–28.7) 21.5 (20.7 to 65.9) 33.3 (0.0–100.0) 2.7 (0.2–29.4)
Entire cohort 39/4,171 69.0 6.8, 4.7 (0.0–40.0) 35.1 (24.0–47.1 44.8 (31.0–59.8) –
PYR person-years, CI confidence interval, HR hazard ratio in a Cox’s proportional hazards model with clustering in order to take into account the
fact that several bones are from the same patients
a In patients with radiotherapy, except for those treated by brachytherapy
b As compared to the general British population: AER absolute excess risk, defined as [(obs 2 exp)/person-years], SIR standardized incidence
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Fig. 3 Hazard ratio for bone sarcoma according to the radiation dose
to the bone; the circles represent observed values by radiation dose,
and vertical bars represent corresponding 95 % CI. The curve is the
prediction using the following model: HR = 1 ? 1.773 * dose; 95 %
CI for 1.773: 0.6213–5.935; six levels of dose represented are no
radiation dose, 0–1, 1–5, 5–15, 15–30 Gy and more than 30 Gy. Note
The upper-bound confidence limit of the last category of dose has
been truncated for better readability
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Several factors add credence to the results presented.
For example, previous medical and treatment data were
collected exhaustively. The response rate in French patients
who were alive when the questionnaire was sent was 75 %,
higher than in the Childhood Cancer Survivor Study
(Robison et al. 2002), and the nonresponders among these
patients were nevertheless followed up for 17 years on
average, whereas British patients were followed up from a
National Cancer Registry. Among cases that were only
registered as cause of death, only the validated ones were
considered as cases in the analyses. Hence, all cases in our
analyses had been confirmed by histopathologists.
In our cohort, the ERR per Gy was 1.78 (95 % CI
0.62–5.94), i.e., the hazard ratio for a dose of 1 Gy was
2.8 (95 % CI 1.6–6.9). This value is lower but compatible
with that expected from the last report on the analysis of
Hiroshima and Nagasaki survivors in which a threshold
dose of 0.85 Gy was observed, with each Gray above this
dose multiplying the risk of bone sarcoma by 7.5 (95 %
CI 1.3–23.1) (Samartzis et al. 2011). Our results are also
compatible with those of Tucker et al. (1987), Hawkins
et al. (1996) and Henderson et al. (2012), although all of
them only considered the local radiation dose. Indeed,
Tucker pointed out an increased risk with an increased
radiation dose, with a relative risk of about 40 for doses
above 60 Gy relative to no radiation. Hawkins et al.
estimated a relative risk of 93.4 (95 % CI 6.8–1,285.4) for
doses between 30 and 50 Gy, which is close to our esti-
mate of 117.9 (36–5,380.6) for doses greater than 30 Gy.
The same conclusions could be drawn from Henderson’s
paper, which exhibits an excess odds ratio per Gray (EOR/
Gy) of 1.32 (95 % CI 0.44–4.22) and an OR of 114.1
(95 % CI 13.5–964.8) for doses higher than 50 Gy.
However, contrary to the findings of Hawkins et al., no
decline in the risk of bone sarcoma was observed for very
high doses (more than 15 Gy). These three papers also
noted an increase in the risk of bone sarcoma if patients
had been treated with chemotherapy, which is consistent
with our results, although we did not identify a drug class
specifically associated with this increase, even when
considering alkylating agents. The cell-killing effect is
known to decrease the radiation dose-related risk at high
doses, because at a given level of dosage all cells die,
even the cancerous ones, and thus, no secondary cancer
could be seen in the organ. However, other issues could be
observed, like the death of the organ. In our analysis, no
cell-killing effect was demonstrated, such as that seen in
other smaller organs such as the thyroid (Sigurdson et al.
2005).
Another childhood cancer survivors’ cohort, which did
not include radiation dose reconstruction, estimated an SIR
of 28.1 (95 % CI 9.1–65.7) and an AER of 28 per 100,000
person-years—values in accordance with our results
(Cardous-Ubbink et al. 2007).
We estimated a higher increase in the risk of bone sar-
coma following high radiation doses than that found in
studies of retinoblastoma survivors (Kleinerman et al.
2005; Wong et al. 1997). This suggests that genetic reti-
noblastoma survivors, who have a much higher baseline
risk than other cancer survivors due to a common genetic
mechanism between retinoblastoma and sarcoma (Friend
et al. 1986), do not exhibit greater sensitivity to radiation.
A sensitivity analysis has been run excluding all retino-
blastoma patients (results not shown); results were similar,
so we kept them in our study to improve statistical power.
The new approach proposed in this article allows the
evaluation of the radiation dose–response relationship in a
cohort analysis, which exhibits a much greater precision
than the usual case–control approach and allows for taking
into account the radiation dose heterogeneity in the body. It
should also avoid selection biases that may be found in
case–control analyses.
Table 4 Bone sarcoma’s risk according to the bone radiation dose
No
radiation
0–1 Gy 1–5 Gy 5–15 Gy 15–30 Gy 30 Gy or more
Bone sarcomas/exposed bones 4/80,643 5/90,574 3/22,306 2/16,467 7/17,060 13/13,658
Median bone radiation dosea
(range)
0 0.2 (0.0–1.0) 2.0 (1.0–5.0) 9.2 (5.0–15.0) 21.5 (15.0–30.0) 38.1 (30.0–179.8)
HRb (95 % CI) 1 (Ref) 1.4 (0.3–5.7) 7.3 (1.6–32.3) 8.2 (1.6–42.9) 38.4 (11.3–130.5) 117.9 (36.5–380.6)
Median local bone radiation
dosea (range)
0 0.2 (0.0–0.7) 2.4 (1.1–4.7) 8.9 (5.2–13.9) 21.8 (16.5–28.2) 42.9 (30.7–73.1)
ORc (95 % CI) 1 (Ref) 2.0 (0.4–9.5) 34.7 (2.2–535.5) 22.2 (1.5–324.0) 415.5 (20.1–8,595.5) 898.0 (27.5–29,325.7)
a Dose in Gray (Gy)
b HR hazard ratio in a Cox’s proportional hazards model with clustering in order to take into account the fact that several bones are from the
same patients, adjustment for age at diagnosis, sex, type of first cancer, chemotherapy and spinal radiation dose, and stratification on the skeleton
parts
c OR odds ratio in a conditional logistic regression in a nested case–control analysis (34 cases/170 controls, matched on sex, age and year of
diagnosis and type of the first cancer), adjustment on chemotherapy and spinal radiation dose
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Conclusion
Based on a cohort of 4,171 survivors of childhood cancer
with a median follow-up of 26 years and 39 incidents of
second bone sarcomas, this study showed that the increase
in the risk of bone sarcoma is well described by a linear
function of the radiation dose received by the bones.
Consequently, the risk of bone sarcoma is mainly a serious
concern at high radiation doses. Also, it seems that almost
all the risk of bone sarcoma is concentrated in the 30 years
following childhood cancer treatment. However, it may be
too early, based on the relatively short follow-up, to reach a
conclusion on this aspect. Lastly, it appears that retino-
blastoma, Ewing’s, soft tissue sarcomas and Hodgkin’s
disease are primary cancer types with the highest risks of
subsequent neoplasm. To conclude, it is crucial to lower
the radiation dose to the bones because the risk of sarcoma
increases continuously with increasing radiation dose to
bones, without plateau. As much as is possible, other
therapeutic solutions should be preferred to radiotherapy in
bone sarcoma-sensitive areas, such as the head or pelvis.
Also, intervention strategies such as screening or preven-
tion of SMNs should be based on first cancer types with the
highest risks of subsequent neoplasm.
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